$51.18
-0.56[-1.08%]
At close: Apr 25
$51.18
0[0.00%]
After Hours: 4:00PM EDT
Latest News for Incyte Stock (NASDAQ:INCY)
Incyte Stock (NASDAQ: INCY)
Categories: All
Wednesday, April 24, 2024
Tuesday, April 23, 2024
- Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst RecommendsVandana Singh - 2 days ago
- Peeling Back The Layers: Exploring Incyte Through Analyst InsightsBenzinga Insights - 2 days ago
- Cantor Fitzgerald Initiates Coverage On Incyte with Neutral RatingBenzinga Newsdesk - 2 days ago
- Incyte To Acquire Escient And Its Assets For $750M Plus Escient's Net Cash Remaining At The Close Of The Transaction, Subject To Customary AdjustmentsCharles Gross - 2 days ago
Monday, April 01, 2024
Monday, March 25, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
- Stifel Reiterates Hold on Incyte, Maintains $68 Price TargetBenzinga Newsdesk - Mar 12, 2024, 12:33PM
- Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)Benzinga Insights - Mar 12, 2024, 12:00PM
- RBC Capital Reiterates Sector Perform on Incyte, Maintains $65 Price TargetBenzinga Newsdesk - Mar 12, 2024, 11:15AM
Monday, March 11, 2024
- Sunday, Incyte Announced Results From A Phase 2 Study Of Povorcitinib (Incb54707), The Study Met Its Primary Endpoint With Improvement In Itch Compared To Placebo In Prurigo NodularisBenzinga Newsdesk - Mar 11, 2024, 5:35AM
- Sunday, Incyte Announced New Results From Phase 2 Study Of Ruxolitinib Cream (Opzelura) In Hidradenitis Suppurativa, The Study Met Its Primary Endpoint, Demonstrating Significant Reduction In Abscess, Inflammatory Nodule Count Versus Vehicle ControlBenzinga Newsdesk - Mar 11, 2024, 5:34AM
Monday, March 04, 2024
Tuesday, February 27, 2024
Friday, February 23, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
- Incyte shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY24 Jakafi net product revenue.Benzinga Newsdesk - Feb 13, 2024, 11:09AM
- Incyte Says Advancing High Potential Pipeline Provides Opportunity For Over 10 New Launches By 2030Benzinga Newsdesk - Feb 13, 2024, 7:12AM
- Incyte Expects 2024 Jakafi Net Product Revenues Of $2.69B-$2.75BBenzinga Newsdesk - Feb 13, 2024, 7:11AM
- Incyte Q4 Adj EPS $1.06 Misses $1.16 Estimate, Sales $1.01B Beat $1.00B EstimateBenzinga Newsdesk - Feb 13, 2024, 7:05AM
- Earnings Scheduled For February 13, 2024Benzinga Insights - Feb 13, 2024, 5:05AM
Tuesday, February 06, 2024
Monday, February 05, 2024
- Incyte Enters Asset Purchase Agreement With Morphosys; Gains Exclusive Global Development And Commercialization Rights To Tafasitamab (Monjuvi)Benzinga Newsdesk - Feb 5, 2024, 4:48PM
- MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug DeveloperErica Kollmann - Feb 5, 2024, 12:31PM
Tuesday, January 23, 2024
- In A Strategic Move, Christiana Stamoulis Acquires Incyte Stock Options: Enhancing ValueBenzinga Insights - Jan 23, 2024, 10:01AM
- Vijay Iyengar Backs Up Beliefs With A Notable Acquisition In Incyte Stock OptionsBenzinga Insights - Jan 23, 2024, 10:01AM
- Insider Activity Spotlight: Steven Stein Acquires In Incyte Stock OptionsBenzinga Insights - Jan 23, 2024, 10:01AM
- PAULA SWAIN Takes A Bullish Stance, Acquiring In Incyte Stock OptionsBenzinga Insights - Jan 23, 2024, 10:01AM
- PABLO CAGNONI Backs Up Beliefs With A Notable Acquisition In Incyte Stock OptionsBenzinga Insights - Jan 23, 2024, 10:01AM
Wednesday, January 10, 2024
Monday, January 08, 2024
Thursday, December 14, 2023
Wednesday, December 13, 2023
- Incyte shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and announced a $78 price target.Benzinga Newsdesk - Dec 13, 2023, 10:27AM
- Expert Ratings for IncyteBenzinga Insights - Dec 13, 2023, 10:00AM
- JMP Securities Reiterates Market Outperform on Incyte, Maintains $93 Price TargetBenzinga Newsdesk - Dec 13, 2023, 9:56AM
- Leerink Partners Upgrades Incyte to Outperform, Announces $78 Price TargetBenzinga Newsdesk - Dec 13, 2023, 8:16AM
Tuesday, December 12, 2023
Monday, December 11, 2023
Thursday, December 07, 2023
Monday, December 04, 2023
Wednesday, November 29, 2023
Wednesday, November 22, 2023
Tuesday, November 21, 2023
- Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, CompetitivenessVandana Singh - Nov 21, 2023, 3:05PM
- The Latest Analyst Ratings for IncyteBenzinga Insights - Nov 21, 2023, 7:00AM
- Goldman Sachs Downgrades Incyte to Neutral, Announces $65 Price TargetBenzinga Newsdesk - Nov 21, 2023, 6:05AM